Limits...
Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life.

Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet JM, Schuster V - BMC Infect. Dis. (2010)

Bottom Line: The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations.The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels.No serious adverse events were reported during the study.

View Article: PubMed Central - HTML - PubMed

Affiliation: University Hospital for Children and Adolescents, Leipzig, Germany. volker.schuster@medizin.uni-leipzig.de

ABSTRACT

Background: Few studies have assessed long term persisting immunity against hepatitis B virus (HBV) in children vaccinated during infancy with combined vaccines containing recombinant HBV surface antigen (HBs). We assessed antibody persistence and immune memory in children 4-5 years of age, previously vaccinated with four doses of combined hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa).

Methods: Immune memory was assessed in 301 children through administration of a challenge dose of monovalent HBV vaccine.

Results: At 4-5 years of age, 85.3% of subjects had persisting anti-HBs antibody concentrations >or= 10 mIU/mL, rising to 98.6% after the HBV challenge dose. All but 12 subjects (95.8%) achieved post-challenge anti-HBs concentrations >or= 100 mIU/mL. The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations. An anamnestic response to the HBV vaccine challenge was observed in 96.8% of subjects, including 17/21 (81.0%) of children with initially undetectable antibodies (<3.3 mIU/mL). All but 4 of 42 subjects (90.5%) with anti-HBs antibodies <10 mIU/mL prior to the challenge dose, achieved seroprotective levels afterwards. A 4-fold rise in antibody concentration after the challenge dose was observed in 259/264 (98.1%) of initially seropositive subjects. The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels. No serious adverse events were reported during the study.

Conclusion: The combined DTPa-HBV-IPV/Hib vaccine induced lasting immune memory against hepatitis B. Long term protection afforded by DTPa-HBV-IPV/Hib is likely to be similar to that observed following priming with monovalent HBV vaccines.

Trial registration: http://www.clinicaltrials.gov 106789 NCT00411697.

Show MeSH

Related in: MedlinePlus

Relationship between anti-HBs antibody concentrations before and after HBV challenge (ATP Immunogenicity cohort).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2821389&req=5

Figure 1: Relationship between anti-HBs antibody concentrations before and after HBV challenge (ATP Immunogenicity cohort).

Mentions: An anamnestic response to the hepatitis B vaccine challenge was observed in 96.8% [95% CI 94.1; 98.5] of subjects (276/285). Of 21 subjects whose pre-challenge anti-HBs antibody level was below 3.3 mIU/mL (i.e. seronegative), 17 (81.0%) reached the 10 mIU/mL seroprotection cut off after the challenge dose. Of 42 subjects who had anti-HBs antibody concentrations below 10 mIU/mL prior to the challenge dose, all but 4 (90.5%) achieved seroprotective anti-HBs levels after the challenge (Table 2). Of 264 subjects with detectable anti-HBs antibodies prior to the challenge dose, 98.1% (259) had at least a 4-fold increase in antibody concentrations following the challenge dose. The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels (Table 2, Figure 1).


Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life.

Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet JM, Schuster V - BMC Infect. Dis. (2010)

Relationship between anti-HBs antibody concentrations before and after HBV challenge (ATP Immunogenicity cohort).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2821389&req=5

Figure 1: Relationship between anti-HBs antibody concentrations before and after HBV challenge (ATP Immunogenicity cohort).
Mentions: An anamnestic response to the hepatitis B vaccine challenge was observed in 96.8% [95% CI 94.1; 98.5] of subjects (276/285). Of 21 subjects whose pre-challenge anti-HBs antibody level was below 3.3 mIU/mL (i.e. seronegative), 17 (81.0%) reached the 10 mIU/mL seroprotection cut off after the challenge dose. Of 42 subjects who had anti-HBs antibody concentrations below 10 mIU/mL prior to the challenge dose, all but 4 (90.5%) achieved seroprotective anti-HBs levels after the challenge (Table 2). Of 264 subjects with detectable anti-HBs antibodies prior to the challenge dose, 98.1% (259) had at least a 4-fold increase in antibody concentrations following the challenge dose. The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels (Table 2, Figure 1).

Bottom Line: The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations.The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels.No serious adverse events were reported during the study.

View Article: PubMed Central - HTML - PubMed

Affiliation: University Hospital for Children and Adolescents, Leipzig, Germany. volker.schuster@medizin.uni-leipzig.de

ABSTRACT

Background: Few studies have assessed long term persisting immunity against hepatitis B virus (HBV) in children vaccinated during infancy with combined vaccines containing recombinant HBV surface antigen (HBs). We assessed antibody persistence and immune memory in children 4-5 years of age, previously vaccinated with four doses of combined hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa).

Methods: Immune memory was assessed in 301 children through administration of a challenge dose of monovalent HBV vaccine.

Results: At 4-5 years of age, 85.3% of subjects had persisting anti-HBs antibody concentrations >or= 10 mIU/mL, rising to 98.6% after the HBV challenge dose. All but 12 subjects (95.8%) achieved post-challenge anti-HBs concentrations >or= 100 mIU/mL. The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations. An anamnestic response to the HBV vaccine challenge was observed in 96.8% of subjects, including 17/21 (81.0%) of children with initially undetectable antibodies (<3.3 mIU/mL). All but 4 of 42 subjects (90.5%) with anti-HBs antibodies <10 mIU/mL prior to the challenge dose, achieved seroprotective levels afterwards. A 4-fold rise in antibody concentration after the challenge dose was observed in 259/264 (98.1%) of initially seropositive subjects. The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels. No serious adverse events were reported during the study.

Conclusion: The combined DTPa-HBV-IPV/Hib vaccine induced lasting immune memory against hepatitis B. Long term protection afforded by DTPa-HBV-IPV/Hib is likely to be similar to that observed following priming with monovalent HBV vaccines.

Trial registration: http://www.clinicaltrials.gov 106789 NCT00411697.

Show MeSH
Related in: MedlinePlus